Navigation Links
OncoMed Pharmaceuticals Announces FDA Clearance to Commence Phase 1 Testing of Anti-Cancer Stem Cell Therapeutic OMP-18R5
Date:4/28/2011

REDWOOD CITY, Calif., April 28, 2011 /PRNewswire/ -- OncoMed Pharmaceuticals, Inc., a company developing novel therapeutics that target cancer stem cells or tumor-initiating cells, today announced that the FDA has accepted an IND filing for OMP-18R5, which allows OncoMed to commence Phase 1 clinical testing.  

OMP-18R5 is a monoclonal antibody that binds selected receptors in the Wnt signaling pathway and is the first antibody to specifically block these targets to enter human studies.  The Phase 1 clinical trial of OMP-18R5 is a single-agent study designed to evaluate the safety of escalating doses of OMP-18R5 in patients with advanced solid tumors.  The study will also assess pharmacokinetics, biomarkers and initial evidence of efficacy.  The Phase 1 trial is being conducted at leading U.S. cancer drug development centers.  Preclinical studies have shown that OMP-18R5 decreases the frequency of tumor-initiating cells across a variety of tumor types.  

"The acceptance from the FDA to begin clinical testing for OMP-18R5 represents an important milestone for OncoMed.  OMP-18R5 is our first Wnt pathway program cleared to begin clinical trials, and we now have three novel agents in the clinic in multiple clinical trials," said Paul Hastings, President and Chief Executive Officer of OncoMed Pharmaceuticals.  "We are excited to continue building and advancing our rich pipeline of first-in-class anti-cancer stem cell therapeutics with the potential to dramatically transform cancer treatment by directly targeting tumor-initiating cells."  

OMP-18R5 is part of OncoMed's collaboration with Bayer HealthCare Pharmaceuticals and its advancement to the clinic triggers a $20M milestone payment from Bayer to OncoMed.  In June 2010, OncoMed and Bayer entered into a broad strategic alliance valued at up to $387.5M per program to develop cancer stem cell antibody and protein therapeutics targeting the Wnt signa
'/>"/>

SOURCE OncoMed Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. OncoMed Chooses SynCo Bio Partners to Fill and Finish its Lead Antibody
2. SynCo Expands Agreement with OncoMed Pharmaceuticals to Manufacture Cancer Stem Cell Antibodies
3. Bayer and OncoMed Pharmaceuticals Enter Strategic Alliance to Develop Anti-Cancer Stem Cell Therapeutics
4. OncoMed Pharmaceuticals Awarded Five Therapeutic Discovery Project Grants Totaling $1.2 Million
5. OncoMed Pharmaceuticals Initiates Phase 1 Clinical Trial of Anti-Cancer Stem Cell Therapeutic OMP-59R5
6. OncoMed Anti-Cancer Stem Cell Antibody OMP-21M18 Demonstrates Potent Activity in Preclinical Studies Against Human Colon Cancer Tumors Regardless of KRAS Mutation Status
7. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
8. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
9. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
10. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
11. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/21/2015)... -- Inmark,s acquisition of Saf-T-Pak last week positioned Inmark ... Division 6.2.  For over 25 years, Saf-T-Pak has ... on IATA, ICAO, US DOT, Transport Canada, RID/ADR ... were particularly interested in Saf-T-Pak,s proprietary Learning Management ... programs," said David Oyler , Inmark President ...
(Date:4/21/2015)... April 21, 2015 Global cap ... World demand for caps and closures will exceed $55 billion ... exceed two trillion annually. Beverages will continue to account for ... and a number of smaller markets are expected to register ... Although the most developed markets -- the US, ...
(Date:4/21/2015)... 2015 The global dermatology diagnostic devices market ... from 2014 to 2019. North America ... shares in the global dermatology diagnostic devices market. The ... mainly attributed to a wide range of factors, such ... dermatologists, and technological advancements made in the field of ...
Breaking Medicine Technology:Inmark's Acquisition Of Saf-T-Pak Results In Expansion Of Its Dangerous Goods Training Portfolio 2World Caps & Closures Market 2World Caps & Closures Market 3Dermatology Diagnostic Devices Market by Product, by End-User - Global Forecast to 2019 2Dermatology Diagnostic Devices Market by Product, by End-User - Global Forecast to 2019 3
... and NEW YORK, July 14, 2011 ... company leveraging its proprietary drug-delivery platforms to develop treatments ... announced that its lead product for oral mucositis, ... benefit network.  Reimbursement coverage for MuGard is now available ...
... BLUE BELL, Pa., July 14, 2011 Inovio Pharmaceuticals, ... in the development of therapeutic and preventive vaccines against ... cell and antibody responses were generated in its Phase ... for the prevention of avian H5N1 influenza delivered using ...
Cached Medicine Technology:Access Pharmaceuticals MuGard Added to CVS Caremark's Pharmacy Benefit Network 2Access Pharmaceuticals MuGard Added to CVS Caremark's Pharmacy Benefit Network 3Inovio Pharmaceuticals Demonstrates Positive Immune Responses in Phase I Clinical Trial of SynCon™ H5N1 Influenza Vaccine and Launches Multi-Subtype Influenza Vaccine Phase I 2Inovio Pharmaceuticals Demonstrates Positive Immune Responses in Phase I Clinical Trial of SynCon™ H5N1 Influenza Vaccine and Launches Multi-Subtype Influenza Vaccine Phase I 3Inovio Pharmaceuticals Demonstrates Positive Immune Responses in Phase I Clinical Trial of SynCon™ H5N1 Influenza Vaccine and Launches Multi-Subtype Influenza Vaccine Phase I 4Inovio Pharmaceuticals Demonstrates Positive Immune Responses in Phase I Clinical Trial of SynCon™ H5N1 Influenza Vaccine and Launches Multi-Subtype Influenza Vaccine Phase I 5Inovio Pharmaceuticals Demonstrates Positive Immune Responses in Phase I Clinical Trial of SynCon™ H5N1 Influenza Vaccine and Launches Multi-Subtype Influenza Vaccine Phase I 6Inovio Pharmaceuticals Demonstrates Positive Immune Responses in Phase I Clinical Trial of SynCon™ H5N1 Influenza Vaccine and Launches Multi-Subtype Influenza Vaccine Phase I 7Inovio Pharmaceuticals Demonstrates Positive Immune Responses in Phase I Clinical Trial of SynCon™ H5N1 Influenza Vaccine and Launches Multi-Subtype Influenza Vaccine Phase I 8Inovio Pharmaceuticals Demonstrates Positive Immune Responses in Phase I Clinical Trial of SynCon™ H5N1 Influenza Vaccine and Launches Multi-Subtype Influenza Vaccine Phase I 9
(Date:4/21/2015)... Somerset, NJ & New York, NY (PRWEB) April ... the leading global provider of advanced delivery technologies ... health products, today announced the launch of ADVASEPT™ ... the safe and efficient delivery of injectable medications. ... syringe, combining a safe, convenient and functional container ...
(Date:4/21/2015)... Spokane, WA (PRWEB) April 21, 2015 ... Medical Practice Edition 2 for otolaryngologists, bringing the ... in the healthcare community. Otolaryngologists can now ... backed by a trusted source in the industry, ... successful integration with leading EHRs. , “Lyft is ...
(Date:4/21/2015)... April 21, 2015 QuickMedical, a ... and supplies, now represents Schiller America's ... ECGs, Stress Tests, and Vital Signs Monitors, among ... Switzerland, is a global leader in the development ... are developed in close cooperation with the world's ...
(Date:4/21/2015)... (PRWEB) April 21, 2015 On April ... Awards” EcoLuxe Lounge at the world famous Avalon Hollywood. ... sustainable product placement in TV and film, the EcoLuxe ... appearances at many awards ceremonies and festivals throughout the ... providers of eco-friendly and socially conscious products and services, ...
(Date:4/21/2015)... The 2015 Market Research Report on ... and in-depth study on the current state of ... a focus on the Chinese situation. , ... research are Cargill, Fbc Industries, Posy Pharmachem, Fuso, ... Lianyungang Mupro Fi, Yixing-Union, Debang Fine Chemical, Shuren ...
Breaking Medicine News(10 mins):Health News:Catalent Announces the Expansion of its Advanced, Aseptic, Glass-Free Injectable Platform with New ADVASEPT™ Lock Delivery Technology 2Health News:Lyft Expands Its Offerings to Include Dragon® Medical Practice Edition 2 for Otolaryngologists. 2Health News:QuickMedical Launches New Product Line: Schiller America 2Health News:QuickMedical Launches New Product Line: Schiller America 3Health News:Hollywood's Santana Dempsey and Choices Recovery South Bend Examine Victory over Personal Struggles 2Health News:Sodium Citrate Industry Global Key Manufacturers Analysis Report 2015-2020 2Health News:Sodium Citrate Industry Global Key Manufacturers Analysis Report 2015-2020 3
... S.D., Dec. 8 LodgeNet Interactive Corporation (Nasdaq: LNET ... hospitality and healthcare businesses, today announced that its Chairman and ... and Communications Conference on Wednesday, December 9, 2009, in New ... its success in proactively managing its business during the evolving ...
... , OAKLAND, Calif., Dec. ... a stress-free and harmonious year. To help people learn to live ... announced that it will dedicate 2010 to teaching people how to ... understanding and integrating one of the Principles, with a year-end intensive ...
... , SOUTH SAN FRANCISCO, Calif., Dec. 8 Anesiva, Inc. ... Anesiva approved the merger with Arcion Therapeutics, Inc. ("Arcion") during ... the merger, Anesiva stockholders also approved a one-for-forty reverse stock ... merger. , Closure of the merger remains contingent ...
... , LONDON, ... providers have gradually changed their perspective regarding the investment in ... solutions to save costs. Market players in the Healthcare IT ... partner with other companies to bring an innovative product to ...
... ... It offers new features for effectively working with Microsoft Office and high performance 64 ... (PRWEB) December ... and a powerful 64-bit capability. To date, InfoZoom has been known as one ...
... ... to announce the opening of a New Baltimore Office. REES believes ... permanent Baltimore presence will help serve our international clients more efficiently and ... Beverly Brandon. Beverly is a long-time resident of Baltimore, Maryland. ...
Cached Medicine News:Health News:LodgeNet Interactive to Participate in UBS' 37th Annual Global Media and Communications Conference 2Health News:LodgeNet Interactive to Participate in UBS' 37th Annual Global Media and Communications Conference 3Health News:LodgeNet Interactive to Participate in UBS' 37th Annual Global Media and Communications Conference 4Health News:LodgeNet Interactive to Participate in UBS' 37th Annual Global Media and Communications Conference 5Health News:The Breema Center Presents a Yearlong Campaign to Transform Stress into Harmony in 2010 and Beyond 2Health News:Anesiva Stockholders Approved Merger With Arcion Therapeutics but Merger Remains Contingent on Other Closing Conditions 2Health News:Anesiva Stockholders Approved Merger With Arcion Therapeutics but Merger Remains Contingent on Other Closing Conditions 3Health News:Frost & Sullivan to Hold Web Conference on Integrated Hospital Pharmacy Information Systems - How to Maneuver towards Growth Potential 2Health News:InfoZoom Launches V6.4 of its Industry Leading In-Memory Data Analysis Software 2Health News:InfoZoom Launches V6.4 of its Industry Leading In-Memory Data Analysis Software 3Health News:REES Announces New Baltimore Office 2
Inquire...
The autoclavable, aluminum needle box is designed to store loaded needles and help protect personnel from exposure. Each shield consists of an aluminum box with faceplate to match the grid pattern th...
... Brachytherapy loaders allow for efficient, easy ... Connectors to your customized plans at ... Bard loaders is the flexibility to ... in the QuickLoad™ Loader allows for ...
... designed to help you achieve one important ... procedure. All needles are engineered for exceptional ... for smooth entry and exit. A broad ... an ideal match with procedural needs and ...
Medicine Products: